[go: up one dir, main page]

WO2009154463A2 - Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme - Google Patents

Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme Download PDF

Info

Publication number
WO2009154463A2
WO2009154463A2 PCT/NL2009/050365 NL2009050365W WO2009154463A2 WO 2009154463 A2 WO2009154463 A2 WO 2009154463A2 NL 2009050365 W NL2009050365 W NL 2009050365W WO 2009154463 A2 WO2009154463 A2 WO 2009154463A2
Authority
WO
WIPO (PCT)
Prior art keywords
butyrate
source
composition
carbohydrate
butyrate source
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2009/050365
Other languages
English (en)
Other versions
WO2009154463A3 (fr
Inventor
Steven Alfons Lieven William Vanhoutvin
Frederik Jan Troost
Robert Jan Maria Brummer
Konraad Venema
Henrike Maria Hamer
Dorothea Maria Agnes Elisa Jonkers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stichting Top Inst Food and Nutrition
Original Assignee
Stichting Top Inst Food and Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Top Inst Food and Nutrition filed Critical Stichting Top Inst Food and Nutrition
Publication of WO2009154463A2 publication Critical patent/WO2009154463A2/fr
Publication of WO2009154463A3 publication Critical patent/WO2009154463A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Definitions

  • the invention relates to a new use of butyrate in human to improve visceral perception.
  • the human large intestine harbours a complex diversity of micro-organisms, which exert both positive and negative effects on gut physiology.
  • the gut microbiota affects, the local and systemic immune system, has a role in the intestinal defense against pathogens and is important in the metabolism of nutrients and toxic compounds [I].
  • the two main types of bacterial metabolism that occur in the gut are saccharolytic and proteolytic fermentation. Saccharolytic fermentation is favorable for the host because it produces short chain fatty acids (SCFAs), such as butyrate, acetate and propionate. A variety of health promoting properties have been attributed to SCFAs. End products of proteolytic fermentation are less favorable, including nitrogenous metabolites, some of which are carcinogenic.
  • the proximal colon is predominantly a site of saccharolytic fermentation, whereas in the distal colon, where carbohydrates are present only in minute amounts, mainly proteolytic fermentation takes place. This may partly explain why many gastrointestinal disorders may occur mainly in the distal colon.
  • butyrate stimulates intestinal mucus production supporting the mucosal barrier function [10, 11], possesses anti- oxidative capacity [12, 13], increases mucosal blood flow [14], and may decrease colonic epithelial permeability [15, 16].
  • a rat study suggested that butyrate causes an increase in colonic sensitivity[17].
  • the present invention demonstrates for the first time that butyrate can be used as a new treatment in human for improving visceral perception and/or decreasing visceral hypersensitivity.
  • the effect of butyrate on visceral perception can be evoked anywhere along this axis ranging from the intestinal microbiota to the brain cortex.
  • a butyrate source for use as a medicament for improving visceral perception and/or inducing a detectable decrease of visceral sensitivity in a human subject.
  • butyrate source means any agent, chemical agent or living agent leading to the production of butyrate.
  • a “butyrate source” may also refer to a given concentration of butyrate directly administered to a human subject as later defined herein.
  • butyrate is produced by the action of a living agent such as a bacterium (i.e. via bacterial digestion or fermentation) which is administered to a human subject and/or which is already present in the intestine of a human subject.
  • a living agent such as a bacterium (i.e. via bacterial digestion or fermentation) which is administered to a human subject and/or which is already present in the intestine of a human subject.
  • butyrate is produced from a chemical agent preferably a carbohydrate.
  • a carbohydrate may be a non-digestible, non-digested or a digestible carbohydrate.
  • a carbohydrate is preferably an oligosaccharide or a polysaccharide.
  • An oligosaccharide is defined herein as a saccharide polymer with a small number (usually 3 to 10) of components sugars, also known as simple sugars.
  • a polysaccharide is a relatively more complex carbohydrate than an oligosaccharide.
  • Polysaccharides are polymers made up of many monosaccharides joined together by glycosidic bonds. More preferably, a carbohydrate is a non-digestible carbohydrate, even more preferably a non-digestible oligosaccharide (NDO) or a non-digestible polysaccharide which is administered to a human subject.
  • NDO non-digestible oligosaccharide
  • butyrate is produced by the combined action of a bacterium and a carbohydrate, wherein both are preferably administered to a human being or wherein only a carbohydrate is administered to a human being.
  • non-digestible carbohydrate preferably means that the human being does not have the intestinal enzymes to digest this carbohydrate.
  • this carbohydrate is expected to be digested or fermented by (endogenous) intestinal bacteria. This digestion or fermentation mainly occurs in the colon.
  • Preferred NDO include fructo-oligosaccharide (FOS), galacto-oligosaccharide (GOS). Inuline is a preferred non-digestible polysaccharide.
  • a source of butyrate comprises a non-digestible carbohydrate, more preferably comprises a NDO, which will be converted at least partly into butyrate in the colon of a human being by the endogenous intestinal bacteria.
  • a non-digested or a digestible carbohydrate is used. When one refers herein to a digestible carbohydrate, it may be that under specific circumstances, this digestible carbohydrate is a non-digested carbohydrate.
  • a non- digested carbohydrate is a carbohydrate which is potentially a digestible carbohydrate as defined below, but which is not digested due to certain circumstances such as transit through the upper intestines, inaccessibiltiy by digestive enzymes (e.g. due to enclosure within a plant cell), or other reasons known to the skilled person in the art.
  • a non-digested or a digestible carbohydrate is preferably formulated so that it will be as less as possible digested or degraded by the enzymes of the human being and will be as much as possible digested or fermented by intestinal bacteria.
  • Such formulations are known to the skilled person as enteric formulations, encapsulations (coatings), and/or slow-release formulations are more extensively described later herein.
  • Such types of formulation may also be used for any other butyrate source as defined herein: for example bacteria and/or non-digestible carbohydrate.
  • digestible carbohydrate are lactose, starch and oligosaccharides derived from starch.
  • a given amount of a digestible carbohydrate, a non-digested carbohydrate, a non-digestible carbohydrate and/or a given amount of a bacterium is administered to a human being.
  • This amount of digestible carbohydrate, non-digested carbohydrate, non-digestible carbohydrate and/or of bacterium is preferably such that an increase of the internal concentration of butyrate in the lumen is inducible and/or detectable (detectable increase compared to the physiological concentration of butyrate) as defined herein.
  • the concentration of butyrate in the lumen is preferably assessed using GC-MS (Gas Chromatograph- Mass Spectrometry) as described in Venema K et al (Venema K, et al (2005), Microbial
  • the increase is detectable when it is of at least 1%, 2%, 5%, 7%, 10%, 15%, 20%, 25%, or more.
  • the physiological concentration of butyrate in the lumen of a human being is ranged between 11 and 25 mM (40).
  • the administration of a butyral source may lead to a concentration of butyrate in the lumen which is ranged between 1.5 and 20 mM, or of at least 2OmM, or of at least 25mM, or of at least 3OmM, or of at least 35mM, or of at least 4OmM, or of at least 45mM, or of at least 5OmM, or of at least 55mM, or of at least 6OmM, or of at least 65mM, or of at least 7OmM, or of at least 75mM, or of at least 8OmM, or of at least 85mM, or of at least 9OmM, or of at least 95mM, or of at least 10OmM.
  • Preferred bacteria include one or more of the following: a food-grade bacterium, a commensal bacterium or a (attenuated) pathogenic bacterium.
  • a bacterium is a food-grade bacterium, particularly a gram-positive bacterium, and more preferably a lactic acid bacterium.
  • a bacterium may also be a probiotic bacterium, which in itself has a beneficial effect when ingested by a subject.
  • a preferred bacterium belongs to a genus selected from the group consisting of Lactobacillus, Lactococcus, Leuconostoc, Carnobacterium, Streptococcus, Bifidobacterium, Bacteroides, Eubacterium, Clostridium, Fusobacterium, Propionibacterium, Enterococcus, Staphylococcus, Peptostreptococcus, and Escherichia.
  • a further preferred bacterium is a Lactobacillus or Bifidobacterium species selected from the group consisting of L. reuteri, L. fermentum, L. acidophilus, L. crispatus, L. gasseri, L. johnsonii, L. plantarum, L.
  • An amount of a bacterium ranged between 10 7 and 10 13 may be administered. Preferably, between 10 9 and 10 11 .
  • quantities of 5 to 30 g of may be orally administered on a daily basis. Preferably, 5 to 15 g a day taken 1-3 times a day.
  • at least 5 g of carbohydrate is administered per day to induce a production of at least 2OmM of butyrate in the lumen.
  • at least 10 to 20 g of carbohydrate is administered per day to induce a production of at least 50 to 100 mM of butyrate in the lumen.
  • An amount of a bacterium ranged between approximately 10 7 and approximately 10 13 may be administered. Preferably, between approximately 10 9 and approximately 10 11 .
  • quantities of approximately 5 to approximately 30 g of may be orally administered on a daily basis. Preferably, approximately 5 to approximately 15 g a day taken 1-3 times a day. In a preferred embodiment, at least approximately 5 g of carbohydrate is administered per day to induce a production of approximately at least 2OmM of butyrate in the lumen.
  • approximately at least 10 to 20 g of carbohydrate is administered per day to induce a production of at least approximately 50 to 100 mM of butyrate in the lumen.
  • a preferred carbohydrate in this context is a non-digestible carbohydrate, more preferably an oligosaccharide, even more preferably a FOS or a GOS.
  • the skilled person may have to adapt the quantity used to reach the desired effect (i.e. increased quantity of butyrate produced in the lumen).
  • a bacterium and/or a digestible carbohydrate and/or a non-digested carbohydrate and/or a non-digestible carbohydrate are suitable for convenient (oral) administration in one or more doses per day or per week.
  • butyrate is a SCFA with a carbon chain length of 4.
  • the term butyrate may encompass the linear unbranched butyrate (n-butyrate) or a branched chain or substituted butyrate.
  • a butyrate source may comprise an amount of butyrate of at least 1 mmol per day administered to a human being or at least 2 mmol/day, or at least 3 mmol/day, or at least 4 mmol/day, or at least 5 mmol/day, or at least 6 mmol/day, or at least 7 mmol/day, or more.
  • a butyrate source may comprise an amount of butyrate of at least approximately 1 mmol per day administered to a human being or at least approximately 2 mmol/day, or at least approximately 3 mmol/day, or at least approximately 4 mmol/day, or at least approximately 5 mmol/day, or at least approximately 6 mmol/day, or at least approximately 7 mmol/day, or more.
  • a butyrate source is a butyrate composition and is preferably for rectal administration, more preferably by rectal enema.
  • An enema is a small bottle (typically 60ml as used in the example) with a long tip, used to infuse a solution (butyrate).
  • a solution of a butyrate source is infused into the rectum using a rectal enema.
  • Rectal enema has been extensively defined in the example. Rectal administration of a butyrate source may also be achieved using suppositories.
  • Other modes of administrations of a butyrate source are not excluded: oral administration using a capsule or a tablet. Such tablet or capsule is preferably an enteric and/or a slow release formulation as later defined herein.
  • a butyrate source may be locally administered via a catheter or a pump.
  • any butyrate source may be used to induce a detectable increase of the internal concentration of butyrate in the lumen as defined herein.
  • An agent that may be used to reach such increase is by accelerating intestinal transit (35).
  • visceral sensitivity is defined as being a subjective sensation thought to originate from the gut and felt by a human being, said sensation being associated with pain such as pain, urge or discomfort.
  • the fact that a subjective sensation associated with pain (i.e. pain, urge or discomfort) is thought to originate from the gut is named "Visceral perception”.
  • Visceral sensitivity or visceral perception is preferably assessed by quantifying at least one of urge pain and discomfort as described in the example by a standardised barostat protocol. Alternatively or in combination with previous preferred embodiment, visceral sensitivity or visceral perception is preferably assessed by measuring the compliance as extensively described in the experimental part.
  • Compliance is preferably assessed using a staircase distension protocol with pressure steps of about 3 mmHg, preferably 3 mmHg with a duration of 30 seconds each, preferably 30 seconds each and a range of 0-33 mmHg.
  • Compliance is a parameter which represents the elasticity of the intestinal wall. It is measured as the volume increase as a result of an increase of lmmHg in intraluminal pressure (expressed as ml/mmHg). The slope of the pressure-volume curve is calculated at the steepest part of the curve. This slope is considered as the dynamic compliance, which may be affected by muscle tone and relaxation due to adaptation. Compliance may also be assessed by using the slope in the highest pressure range of the curve. This slope represents the static compliance, which may be less depending on muscle tone but more on elasticity of connective tissue. In the context of the invention, compliance is synonymous of dynamic compliance, which is inversely related to abdominal complaints.
  • visceral perception is preferably not linked with a specific disease or condition. Visceral perception may be altered as a result of e.g. an alteration in the composition of the intestinal intra-luminal content, changes in serotonergic activity of either the intestine and/or the brain, physiological and/or psychological stress and any alteration of intestinal barrier function.
  • a use of a butyrate source as defined herein may lead to an improvement of visceral perception or a detectable decrease of visceral sensitivity in a treated individual. It preferably means that at least one of urge, pain and discomfort is statistically significantly decreased and/or compliance is statistically significantly increased in said individual as assessed in the standardised barostat protocol as defined in the example.
  • a subject wherein a detectable decrease of visceral sensitivity has been reached was a healthy subject at the onset of the treatment.
  • a pain score higher or equal to 10% at a pressure of 23mmHg or lower indicates that a subject suffers from altered visceral perception.
  • the decrease is preferably measured by comparison with the value of the corresponding parameter in a healthy or control subject.
  • a subject has an altered visceral perception and as a result of a use of a butyrate as defined in the invention, said subject has an improved visceral perception.
  • improving visceral perception is distinct from treating visceral hypersensitivity.
  • Visceral hypersensitivity may be caused by any disease or condition originating from anywhere along the brain-gut axis and its associated systems such as intermediary metabolism and the immune system.
  • Visceral hypersensitivity may be caused by a disease or condition of the gut.
  • Visceral hypersensitivity may also be caused by an alteration in brain function.
  • the use of a butyrate source as defined herein, preferably an amount of butyrate of at least 1 or at least 2 mmol/day or approximately at least 1 or at least 2 mmol/day and/or of a butyrate source which is able to induce a detectable increase of the amount of butyrate in the lumen is said to be functional (i.e. to be used for improving visceral perception ) when such butyrate source induces a statistically significant decrease of at least one of urge, pain and discomfort and/or a statistically significant increase of compliance as assessed in the standardised barostat protocol as defined in the example.
  • a butyrate source is said to be functional in the lumen when such butyrate source induces a detectable decrease of visceral sensitivity or an improvement of visceral perception, which is synonymous of inducing a statistically significant decrease of at least one of urge, pain and discomfort and/or a statistically significant increase of compliance as assessed in the standardised barostat protocol as defined in the example.
  • the decrease of at least one of pain urge and discomfort is preferably assessed by comparison with the initial value of a parameter in the subject before treatment.
  • a decrease means that at least one of these parameters will approximately reach a physiological level of a corresponding control healthy subject not suffering from altered visceral perception. Approximately in this context may mean at least 1% difference with the corresponding value of a healthy subject or at least 5%, 10% difference with the corresponding value of a corresponding healthy subject not suffering from altered visceral perception.
  • the increase of compliance is preferably assessed by comparison with the initial value of said parameter in a subject before treatment.
  • an increase means that said parameter will approximately reach a physiological level of a corresponding control healthy subject not suffering from altered visceral perception.
  • Approximately in this context may mean at least 1% difference with the corresponding value of a healthy subject or at least 5%, 10% difference with the corresponding value of a corresponding healthy subject not suffering from altered visceral perception..
  • a statistically significant increase or decrease as used herein preferably means that using the standardised barostat protocol as defined in the example with 11 subjects, based on the linear part of the curve of figures 3, 4 ,5, and 6 we obtain:
  • a subject does not suffer from an altered visceral perception and the use of a source of butyrate as defined herein will induce a decrease of the perception of the visceral sensitivity of said subject (decrease of at least one of urge, pain and discomfort and/or increase of compliance) or improvement of visceral perception.
  • the term "decrease" has already be defined herein.
  • an organism or an individual or a subject is an human being.
  • an organism treated is suspected to have a high risk of developing an alteration of visceral perception due for example to potential genetic predisposition, and/or to the age of the subject and/or to the lifestyle of a subject (for example nutritional habit and/or to the absence of physical activity).
  • a subject to be treated may be healthy.
  • prevention shall be understood to include complete prevention, prophylaxis, as well as statistically significantly decreasing the individual's risk of getting an altered visceral perception, preferably statistically significantly decreasing at least one of urge, pain and discomfort.
  • the term shall also be understood to include alleviation of any of the symptoms associated with altered visceral perception (i.e. urge, pain and/or discomfort and/or compliance) already developed.
  • treatment or “treating” is understood the management and care of a patient for the purpose of combating the altered visceral perception.
  • treating is also herein synonymous of "delaying" the development of any of the symptoms associated with altered visceral perception (i.e. urge, pain and/or discomfort and/or compliance), preferably associated with increased visceral sensitivity.
  • the delay in the development of a symptom is of approximately at least one day, one week or more or of at least one day, one week or more.
  • a source of butyrate comprises at least one of: at least 5 g of a carbohydrate as defined herein, an amount of butyrate of approximately at least 1 or at least 2 mmol and - between approximately 10 7 and approximately 10 13 bacteria.
  • a source of butyrate comprises at least one of: at least 5 g of a carbohydrate as defined herein, an amount of butyrate of at least 1 or at least 2 mmol and - between 10 7 and 10 13 bacteria.
  • Said source of butyrate is preferably designed to be administered on a daily basis.
  • Said source of butyrate has been extensively defined earlier on.
  • composition in a second aspect, there is provided a composition, preferably a food composition or a pharmaceutical composition comprising a butyrate source as defined herein. More preferably, a pharmaceutical composition comprises a butyrate source and at least one inert excipient.
  • an additional active ingredient may be present in a food or pharmaceutical composition.
  • an additional SCFA selected from the group comprising of acetate, propionate, valerate and caproate.
  • additional active ingredients in a pharmaceutical composition may be an ingredient which is normally classically used for treating an altered visceral perception such as a laxating agent, a spasmolithicum, a painkiller such as paracetamol and/or an anti-inflammatory agent.
  • compositions for enteral or oral administration may be either food compositions or pharmaceutical compositions whereas compositions for rectal administration will usually be pharmaceutical compositions.
  • Pharmaceutical compositions will usually comprise a pharmaceutical carrier in addition to a source of butyrate. The formulation of a composition depends on the intended mode of administration and (therapeutic) application and on the source of butyrate chosen.
  • a pharmaceutical carrier can be any compatible, non toxic substance suitable to deliver a butyrate source to the GI-tract of a subject. E.g. sterile water, or inert solids or excipient may be used as the carrier usually complemented with pharmaceutically acceptable adjuvants, buffering agents, dispersing agents, and the like.
  • Compositions will either be in liquid, e.g.
  • a stabilized suspension of a butyrate source or in solid and/or dry forms, e.g. a powder of lyophilized bacteria.
  • the bacteria can be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. Rectal administration may be via a rectal enema as earlier defined herein.
  • a butyrate source or composition is liquid or semi liquid.
  • rectal administration may be using suppositories.
  • a butyrate source or composition is solid or semi solid.
  • bacteria may be present in a solid dosage form.
  • the bacteria as used in the invention may be dried and later on mixed with inactive ingredients and/or excipients and optionally encapsulated with for example gelatin to form gelatine capsules. Alternatively, the bacteria may be tabletted.
  • Inactive ingredients or inert excipients are such as flavoring agents, stabilizers, sugars or other energy sources, buffering agents, thickeners, diluents, dispersing aids, emulsifiers, and/or binders.
  • inactive agents are: glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate and the like.
  • the bacteria may also be first added in a liquid form, after which the combination is dried.
  • a carbohydrate enriched media such as a dairy product, preferably milk may be used to this end.
  • a preferred composition according to the invention is suitable for consumption by a subject, preferably a human. Such compositions may be in the form of a food supplement or a food or food composition, which besides a butyrate source also contains a suitable food base.
  • a food or food composition is herein understood to include liquids for human consumption, i.e. a drink or beverage.
  • the food or food composition may be a solid, semi-solid and/or liquid food or food composition, and in particular may be a dairy product, such as a fermented dairy product, including but not limited to a yoghurt, a yoghurt-based drink or buttermilk.
  • Such foods or food compositions may be prepared in a manner known per se, e.g. by adding a butyrate source to a suitable food or food base, in a suitable amount.
  • a butyrate source or composition intended for oral administration at least part or all of a butyrate source or composition may be formulated in a capsule, an enteric formulation and/or a slow- release formulation.
  • Such capsule and/or formulation are well known to the skilled person (36, 37, 38, 39).
  • the bacteria are micro-organisms that are used in or for the preparation of a food or food composition, e.g. by fermentation. Examples of such bacteria include lactic acid bacteria, such as probiotic lactic acid strains as earlier exemplified herein.
  • the bacteria as used in the invention may be used in a manner known per se for the preparation of such fermented foods or food compositions, e.g. in a manner known per se for the preparation of fermented dairy products using lactic acid bacteria.
  • the bacteria as used in the invention may be used in addition to the micro-organism usually used, and/or may replace one or more or part of the micro-organism usually used.
  • a food grade lactic acid bacterium as used in the invention may be added to or used as part of a starter culture or may be suitably added during such a fermentation or may be added at the end of a fermentation.
  • a lactic acid bacterium is added at the end of the fermentation.
  • a butyrate source or a composition comprising a butyrate source for the manufacture of a medicament for improving visceral perception in a human subject. All features of this use concerning the identity of the butyrate source, the types of composition used, the definition of visceral perception have already be defined herein.
  • the verb "to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
  • the verb "to consist” may be replaced by "to consist essentially of meaning that butyrate or a composition as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention.
  • reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there be one and only one of the elements.
  • the indefinite article “a” or “an” thus usually means “at least one”.
  • the word “ approximately” or “about” when used in combination with a numerical value preferably means that said value +/- 1% of said value is encompassed by the present invention.
  • the word “ approximately” or “about” when used in combination with an integer preferably means that the invention also encompasses said integer minus 1 or said integer plus 1 (as example: 4 or 5 or 6 are encompassed by the present invention).
  • Figure 1 Design of barostat study consisting of 3 randomised cross-over test periods of 7 days, interspaced with 14 days wash-out period.
  • FIG. 1 A commercially available catheter dedicated for rectal barostat measurements, (non-compliant poly-ethylene balloon with a volume of ca 600ml, connected to a double lumen catheter enabling intra-balloon pressure measurements)
  • Figure 3 The effect of 60 ml of a placebo, 5OmM or 10OmM butyrate (0, 3, 6 mmol of butyrate) intervention on pain scores measured on 100mm visual analogue scales.
  • Figure 4 The effect of 60 ml of a placebo, 5OmM or 10OmM butyrate (0, 3, 6 mmol of butyrate) intervention on urge scores measured on a six-point scale ranging from no urge (0) to maximal urge/ emergency stop (5)
  • Figure 5 The effect of 60 ml of a placebo, 5OmM or 10OmM butyrate (0, 3, 6 mmol of butyrate) intervention on discomfort scores measured on 100mm visual analogue scales.
  • Study design The study design consisted of three periods of one week, with a wash-out period of 2 weeks in between two test weeks, in which the volunteers self-administered rectal enemas containing a 60 ml solution of either, butyrate (10OmM), butyrate (5OmM) or placebo (saline) daily.
  • the enemas were administered just prior to sleeping.
  • the first 20 minutes after administration of the enema the volunteers were instructed to stay on their left side.
  • the enemas were made isotonic with sodium chloride at a pH of 7. Barostat measurements were performed at the start and the end of each test week ( Figure 1). Prior to the study onset, each volunteer performed a "screening" barostat measurement to exclude possible learning effects that could bias the study measurements.
  • Visceral sensitivity was measured using a highly standardised barostat protocol composed of several components. After arrival, the volunteer self-administered a rectal enema containing 60ml of saline. Five minutes after administration of the enema, subjects were instructed to void rectal contents in order to clean the rectum.
  • a commercially available barostat balloon (Mui Scientific, part: C7-2CB-R, see figure 2) was lubricated with KY gel (Johnsson & Johnsson) and inserted rectally 3 cm proximal to the anal sphincter. After a 5 minutes habituation period, the balloon was attached to the barostat equipment (Distender II, G&J electronics, Ontario, Canada) and the barostat procedure was started. The controlled distensions of the balloon were programmed using the standard software package of the barostat equipment (Protocol Plus Deluxe, version 6_7 ).
  • This very short part of the protocol consists of 1 single distension of 2020 mmHg during 1 minute and is needed to ensure the balloon is placed correctly without folds and wrinkles that may impair the airflow.
  • MDP Minimal Distension Pressure
  • the next part of the protocol consisted of a stepwise distension protocol with pressure steps of 1 mmHg with a duration of 30 seconds and a range from 0-20 mmHg.
  • the MDP was defined as the first pressure at which respiratory curves were present in the volume recording of the balloon.
  • the entire protocol was followed, independent from the height of the measured MDP and therefore directly served as a sensitisation step prior to the compliance and perception measurements.
  • the obtained MDP value was set as a reference point (set to zero).
  • This part of the protocol designed for compliance measurement, which represents the elasticity of the rectum in ml/mmHg, consisted of a staircase distension protocol with pressure steps of 3 mmHg with a duration of 30 seconds each and a range of 0-33 mmHg
  • the distension protocol consisted of semi-random distensions (4,13,10,19,16,25,22,31,28,37,34,43,40,49,46,55,52,61,58,67,64,71 mmHg), with a duration of 1 minute, interspaced with 30 second intervals at MDP.
  • VAS Visual Analogue Scale
  • the pain and discomfort data were analyzed using a Gaussian non-linear regression.
  • the urge data is a six level ordinal variable of interest. It therefore was analyze using a mixture of a logistic distribution (parameterized as a proportional-odds) and a gamma distribution (to introduce a frailty dependence) (33).
  • the mean regression was imposed through the time variable to follow a logistic ('S-shape') curve.
  • the model included pressure, 'mdp', first sensation, procedure (treated or not), and carry over effect as explanatory variables.
  • the inference criterion used for comparing the models is their ability to predict the observed data, i.e. models are compared directly through their minimized minus log-likelihood.
  • AIC Akaike information criterion
  • Rosignoli P., et al., Protective activity of butyrate on hydrogen peroxide- induced DNA damage in isolated human colonocytes and HT29 tumour cells. Carcinogenesis, 2001. 22(10): p. 1675-80.
  • Bourdu, S., et al., Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une nouvelle utilisation d'une source de butyrate chez l'homme afin d'améliorer la perception viscérale.
PCT/NL2009/050365 2008-06-20 2009-06-19 Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme Ceased WO2009154463A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7419708P 2008-06-20 2008-06-20
EP08158687.7 2008-06-20
EP08158687 2008-06-20
US61/074,197 2008-06-20
EP09160278.9 2009-05-14
EP09160278 2009-05-14

Publications (2)

Publication Number Publication Date
WO2009154463A2 true WO2009154463A2 (fr) 2009-12-23
WO2009154463A3 WO2009154463A3 (fr) 2010-06-17

Family

ID=41434577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2009/050365 Ceased WO2009154463A2 (fr) 2008-06-20 2009-06-19 Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme

Country Status (1)

Country Link
WO (1) WO2009154463A2 (fr)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017148596A1 (fr) * 2016-03-04 2017-09-08 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
US20170360856A1 (en) 2015-06-15 2017-12-21 4D Pharma Research Limited Compositions comprising bacterial strains
US20180078585A1 (en) 2015-11-20 2018-03-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
US10058574B2 (en) 2015-06-15 2018-08-28 4D Pharma Research Limited Compositions comprising bacterial strains
US10080772B2 (en) 2016-07-13 2018-09-25 4D Pharma Plc Compositions comprising bacterial strains
US10086021B2 (en) 2016-12-12 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10226489B2 (en) 2014-12-23 2019-03-12 4D Pharma Research Limited Composition of bacteroides thetaiotaomicron for immune modulation
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002732D0 (sv) * 1990-08-24 1990-08-24 Kabivitrum Ab Product containing growth factor
FR2837711B1 (fr) * 2002-03-28 2005-05-06 Agronomique Inst Nat Rech Utilisation de la lactobacillus farciminis pour la prevention ou le traitement de pathologies digestives
FR2902978B3 (fr) * 2006-06-29 2008-05-02 Roux Jean Francois Le Additif nutrionnel constitue de microparticules non pulverulentes, compose de sel d'acide butyrique, synthetise en phase lipidique liquide puis solidifie par refroidissement a temperature ambiante

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11013773B2 (en) 2011-07-14 2021-05-25 4D Pharma Research Limited Lactic acid bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US10851137B2 (en) 2013-04-10 2020-12-01 4D Pharma Research Limited Polypeptide and immune modulation
US11414463B2 (en) 2013-04-10 2022-08-16 4D Pharma Research Limited Polypeptide and immune modulation
US10456444B2 (en) 2014-12-23 2019-10-29 4D Pharma Research Limited Pirin polypeptide and immune modulation
US11723933B2 (en) 2014-12-23 2023-08-15 Cj Bioscience, Inc. Composition of bacteroides thetaiotaomicron for immune modulation
US10973872B2 (en) 2014-12-23 2021-04-13 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10226489B2 (en) 2014-12-23 2019-03-12 4D Pharma Research Limited Composition of bacteroides thetaiotaomicron for immune modulation
US11389493B2 (en) 2015-06-15 2022-07-19 4D Pharma Research Limited Compositions comprising bacterial strains
US10322151B2 (en) 2015-06-15 2019-06-18 4D Pharma Research Limited Compositions comprising bacterial strains
US11331352B2 (en) 2015-06-15 2022-05-17 4D Pharma Research Limited Compositions comprising bacterial strains
US10736926B2 (en) 2015-06-15 2020-08-11 4D Pharma Research Limited Compositions comprising bacterial strains
US11040075B2 (en) 2015-06-15 2021-06-22 4D Pharma Research Limited Compositions comprising bacterial strains
US11273185B2 (en) 2015-06-15 2022-03-15 4D Pharma Research Limited Compositions comprising bacterial strains
US11433106B2 (en) 2015-06-15 2022-09-06 4D Pharma Research Limited Compositions comprising bacterial strains
US10493112B2 (en) 2015-06-15 2019-12-03 4D Pharma Research Limited Compositions comprising bacterial strains
US10744167B2 (en) 2015-06-15 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10058574B2 (en) 2015-06-15 2018-08-28 4D Pharma Research Limited Compositions comprising bacterial strains
US10864236B2 (en) 2015-06-15 2020-12-15 4D Pharma Research Limited Compositions comprising bacterial strains
US10391130B2 (en) 2015-06-15 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10780134B2 (en) 2015-06-15 2020-09-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10500237B2 (en) 2015-06-15 2019-12-10 4D Pharma Research Limited Compositions comprising bacterial strains
US20170360856A1 (en) 2015-06-15 2017-12-21 4D Pharma Research Limited Compositions comprising bacterial strains
US10610550B2 (en) 2015-11-20 2020-04-07 4D Pharma Research Limited Compositions comprising bacterial strains
US10471108B2 (en) 2015-11-20 2019-11-12 4D Pharma Research Limited Compositions comprising bacterial strains
US20180078585A1 (en) 2015-11-20 2018-03-22 4D Pharma Research Limited Compositions comprising bacterial strains
US10357520B2 (en) 2015-11-20 2019-07-23 4D Pharma Research Limited Compositions comprising bacterial strains
US11058732B2 (en) 2015-11-20 2021-07-13 4D Pharma Research Limited Compositions comprising bacterial strains
US10744166B2 (en) 2015-11-23 2020-08-18 4D Pharma Research Limited Compositions comprising bacterial strains
US10391128B2 (en) 2015-11-23 2019-08-27 4D Pharma Research Limited Compositions comprising bacterial strains
US10034937B2 (en) 2015-12-04 2018-07-31 Mead Johnson Nutrition Company Synergistic nutritional compositions and uses thereof
US10086023B2 (en) 2016-03-04 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
WO2017148596A1 (fr) * 2016-03-04 2017-09-08 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
EA035949B1 (ru) * 2016-03-04 2020-09-04 4Д ФАРМА ПиЭлСи Применение композиции, содержащей бактериальный штамм вида blautia hydrogenotrophica, и способ лечения или предотвращения висцеральной гиперчувствительности
US20220257667A1 (en) * 2016-03-04 2022-08-18 4D Pharma Plc Compositions comprising bacterial strains
JP2019048857A (ja) * 2016-03-04 2019-03-28 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ 細菌株を含む組成物
US10583158B2 (en) 2016-03-04 2020-03-10 4D Pharma Plc Compositions comprising bacterial strains
CN108883139B (zh) * 2016-03-04 2022-04-26 4D制药有限公司 包含细菌菌株的组合物
US10086022B2 (en) 2016-03-04 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
AU2017226831B2 (en) * 2016-03-04 2018-10-04 4D Pharma Plc Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity
EP3520801A1 (fr) * 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
JP2018534235A (ja) * 2016-03-04 2018-11-22 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ 細菌株を含む組成物
CN108883139A (zh) * 2016-03-04 2018-11-23 4D制药有限公司 包含细菌菌株的组合物
US10960031B2 (en) 2016-07-13 2021-03-30 4D Pharma Plc Compositions comprising bacterial strains
US10610548B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Compositions comprising bacterial strains
US10080772B2 (en) 2016-07-13 2018-09-25 4D Pharma Plc Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US10967010B2 (en) 2016-07-13 2021-04-06 4D Pharma Plc Compositions comprising bacterial strains
US10610549B2 (en) 2016-07-13 2020-04-07 4D Pharma Plc Composition comprising bacterial strains
US10086020B2 (en) 2016-07-13 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10086021B2 (en) 2016-12-12 2018-10-02 4D Pharma Plc Compositions comprising bacterial strains
US10543238B2 (en) 2016-12-12 2020-01-28 4D Pharma Plc Compositions comprising bacterial strains
US10898526B2 (en) 2016-12-12 2021-01-26 4D Pharma Plc Compositions comprising bacterial strains
US10485830B2 (en) 2016-12-12 2019-11-26 4D Pharma Plc Compositions comprising bacterial strains
US11633486B2 (en) 2017-04-17 2023-04-25 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US12186402B2 (en) 2017-04-17 2025-01-07 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US11382936B2 (en) 2017-05-22 2022-07-12 4D Pharma Research Limited Compositions comprising bacterial strains
US11376284B2 (en) 2017-05-22 2022-07-05 4D Pharma Research Limited Compositions comprising bacterial strains
US11123378B2 (en) 2017-05-22 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US10987387B2 (en) 2017-05-24 2021-04-27 4D Pharma Research Limited Compositions comprising bacterial strain
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US12048720B2 (en) 2017-06-14 2024-07-30 Cj Bioscience, Inc. Compositions comprising bacterial strains

Also Published As

Publication number Publication date
WO2009154463A3 (fr) 2010-06-17

Similar Documents

Publication Publication Date Title
WO2009154463A2 (fr) Le butyrate comme médicament permettant d'améliorer la perception viscérale chez l'homme
Campos-Perez et al. Effects of short chain fatty acids on metabolic and inflammatory processes in human health
Gill et al. Short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders
JP6416308B2 (ja) プレバイオティクスとしての、精製された２’−フコシルラクトース、３−フコシルラクトース、およびラクトジフコテトラオースの使用
De Vrese et al. Probiotics and prebiotics: effects on diarrhea
Macfarlane et al. Bacterial metabolism and health‐related effects of galacto‐oligosaccharides and other prebiotics
AU2011340880B2 (en) Oligosaccharide composition for treating skin diseases
RU2469558C2 (ru) Применение пробиотиков и волокон при диарее
Gyawali et al. The role of prebiotics in disease prevention and health promotion
KR20210013352A (ko) 비만 및 비만 관련 질환을 치료하기 위한 프로바이오틱 조성물 및 방법
Yarahmadi et al. Understanding the complex function of gut microbiota: its impact on the pathogenesis of obesity and beyond: a comprehensive review
BR112012008005B1 (pt) composição compreendendo cepas de lactobacillus plantarum
DE102010009582A1 (de) Mittel zur Anwendung bei Lactasemangel und Lactoseintoleranz
WO2020239724A1 (fr) Compositions comprenant du 2-fucosyllactose et du gos
WO2010117274A1 (fr) Glucides permettant l'amélioration de la production d'un acide gras à chaîne courte c5 et/ou c6
WO2023161315A1 (fr) Compositions et procédés pour réduire l'apparition de diarrhée en favorisant blautia obeum dans le microbiote intestinal
US20200113953A1 (en) Composition and method for maintaining healthy kidney function
Winarti et al. The Consumption of Galactomannan Effervescent Drinks made from Coconut Pulp Waste and Colonic Microbiota in Wistar Rats.
Leo et al. Probiotics beverages: An alternative treatment for metabolic syndrome
KR102791846B1 (ko) 인체에서 체지방량을 감소시키기 위한 조성물 및 이의 용도
Abdulamir et al. The role of diet, prebiotic and probiotic in the development and management of inflammatory bowel diseases (IBD)
Dharmatti Prebiotics in Obesity Management
Khan et al. Epistemology of Probiotics
WO2025099321A1 (fr) Compositions comprenant des oligosaccharides de lait humain et des cellules inactivées d'un micro-organisme
KR20250105751A (ko) 모유 올리고당 혼합물 및 프로바이오틱 균주를 유효성분으로 포함하는 신바이오틱 조성물

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09766881

Country of ref document: EP

Kind code of ref document: A2